Gilead Sciences, Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Somatogen, Inc.

Gilead Calistoga LLC

Virginia Commonwealth University

Center for Innovative Technology

Allos Therapeutics, Inc.

Peak Biosciences, Inc.

Baxter Biotech Technology Sarl

Gilead Colorado, Inc.

Abbvie Deutschland Gmbh and Co Kg

Michael J Gerber

Donald J Abraham

Christopher Dufton

Bing Shi

Jerry B Evarts

Fang Wang

Ernest A Carra

Duong D Tran

Keiko Sujino

Richard J Gorczynski

Robert L Roden

Douglas L Looker

Bruce A Kerwin

Stephen L Warren

James E Matsuura

Richmond E Danso-Danquah

Gajanan S Joshi

William D Dalke

Stephen J Hoffman

Telih Boyiri

Kevin Lillehei

Changquing Wang

Thomas A Jellison

Gary J Rosenthal

Duong Tran

Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.

Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one

A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.

Method for treating a pulmonary hypertension condition

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelia A (ET) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETreceptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETreceptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETreceptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETreceptor antagonist.

Therapy for complications of diabetes

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETreceptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETreceptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETreceptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETreceptor antagonist.

[object Object]

A catheter system adapted for navigating, guiding and implanting a catheter or a plurality of catheters in a spatially-defined implantation within the tissue of a patient is provided. The system can include a tissue navigation system and a probe to inform the navigation system to guide emplacement of the catheters within a target tissue. The probe can provide images, such as fiberoptic visual images, or ultrasound images, or can provide radiolocation data, to guide the catheter emplacement. The catheters supply a pressurized liquid including a bioactive agent, such as can be used in the treatment of cancer, for example 123I- or 125I-IUDR. The system and methods provided can be used in the treatment of locally advanced tumors, such as cancers of the brain, head or neck, esophagus, prostate, ovary, liver, pancreas, bladder or rectum.

Guidance and implantation of catheters

A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent. Thus, not only does the combination effectively kill the transit amplifying cell population, the most rapidly replicating type of cell in a tumor, but it also effectively kills the tumor stem cells, which give rise to the transit amplifying cells, for a longer lasting anticancer effect.

Methods of treatment of androgenic steroidal hormone dependent cancer with auger electron-emitting nucleoside analogs

Method for obtaining BOLD MRI images with allosteric effector compounds are disclosed. Methods for the determination of tumor oxygenation and for an optimal time for initiating radiation therapy are also disclosed.

Methods and reagents to acquire MRI signals and images

The present invention relates to a hemoglobin compositions stabilized against the formation of aggregates. The present invention further relates to methods of making such hemoglobin compositions.

Stabilized compositions containing hemoglobin

Chemical structures have been identified which allosterically modify pyrvate kinase and either inhibit or activate enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate.

Allosteric inhibitors of pyruvate kinase

Growing community of inventors

Denver, CO, United States of America

Michael J Gerber